Background and aims Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Here, we present 150 patients with SLE attending our clinic between January and November 2016.
Methods Demographics, clinics, laboratory findings, Systemic Lupus Erythematous Disease Activity Index (SLEDAI), Systemic Lupus International Clinics (SLICC)/American College of Rheumatology (ACR) damage index scores and treatments were analysed. Diagnosis was confirmed with 1997 ACR or 2012 SLICC classifications. Chi-squared or Fisher’s exact tests were used for statistical analysis.
Conclusions SLICC damage was positive in patients receiving pulse steroids (57%), cyclophosphamide (51%), rituximab (73%). In long term, 3 (2%) patients had pulmonary hypertension, 21 (14%) had avascular necrosis, 6 (4%) had malignancy. SLE is an autoimmune disease requiring multi-faceted approach.
- © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.